Ibrutinib capsules 140 mg is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Imbruvica is used to treat certain types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL), Waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in people with or without 17p deletion.
Imbruvica 140mg is also used to treat marginal cell lymphoma and chronic graft-versus-host disease. It is sometimes given when other medicines have not been effective.
Imbruvica 140mg was approved to treat mantle cell and marginal lymphomas by the US Food and Drug Administration (FDA) on an “accelerated” basis. In clinical studies, some people responded to this medicine, but further studies are needed.
IMBRUVICA 140MG COMPOSITION
Ibrutinib
IMBRUVICA 140MG COMPANY NAME
Janssen Pharmaceuticals
IMBRUVICA 140MG HOW TO WORK
Imbruvica 140mg Capsule is a Bruton’s tyrosine kinase inhibitor. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
WHAT IS IMBRUVICA 140MG
buy generic ibrutinib online is available as immediate-release oral capsules and immediate-release oral tablets.
Imbruvica 140mg (ibrutinib) capsules for oral administration are available in the following dosage strengths: 70 mg and 140 mg. Each capsule contains ibrutinib (active ingredient) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide (70 mg capsule only), and black ink.
Imbruvica cost for oral administration are available in the following dosage strengths: 140 mg, 280 mg, 420 mg, and 560 mg. Each tablet contains ibrutinib (active ingredient) and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The film coating for each tablet contains ferrosoferric oxide (140 mg, 280 mg, and 420 mg tablets), polyvinyl alcohol, polyethylene glycol, red iron oxide (280 mg and 560 mg tablets), talc, titanium dioxide, and yellow iron oxide (140 mg, 420 mg, and 560 mg tablets).
IMBRUVICA 140MG HOW TO TAKE
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it.
MECHANISM ACTION OF IMBRUVICA 140MG
Bruton’s tyrosine kinase (BTK) inhibitor; forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity; BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways.
BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion.
IMBRUVICA 140MG DRUG INTERACTIONS
Coadministration with a strong or moderate CYP3A inhibitors may increase ibrutinib plasma concentrations and drug-related toxicities
Coadministration with strong CYP3A inducers may decrease ibrutinib concentrations
Avoid grapefruit and Seville oranges during treatment, as these contain moderate CYP3A4 inhibitors
atazanavir
bosentan
carbamazepine
ciprofloxacin
clarithromycin
nefazodone
nelfinavir
nevirapine
nicardipine
venetoclax
verapamil
IMBRUVICA 140MG SIDE EFFECTS
bladder pain
chest pain
chills
confusion
headache
increased thirst
irregular heartbeat
itching
loss of appetite
nausea and vomiting
rapid weight gain
unusual tiredness or weakness
IMBRUVICA 140MG WARNING
To make sure Imbruvica is safe for you, tell your doctor if you have ever had:
liver or kidney disease;
an active infection;
a bleeding or blood clotting disorder;
a heart rhythm disorder;
risk factors for heart disease (such as diabetes, smoking, being overweight, having high blood pressure or high cholesterol)
surgery; or
a condition for which you take a blood thinner (warfarin, Coumadin, Jantoven).
Using Imbruvica may increase your risk of developing other types of cancer, such as skin cancer. Ask your doctor about your specific risk.
Ibrutinib can harm an unborn baby. Both men and women using this medicine should use birth control to prevent pregnancy. The use of this medicine by either parent may cause harm to the baby.
Keep using birth control for at least 1 month after your last dose of Imbruvica. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using this medicine.
It is not known whether ibrutinib passes into breast milk. It may not be safe to breast-feed a baby while you are using this medicine. Ask your doctor about any risks.
IMBRUVICA 140MG PRECAUTION
Fatal and non-fatal infection (including bacterial, viral, or fungal) reported; 25-26% of patients had ≥Grade 3; consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections; monitor and evaluate patients for fever and infections and treat appropriately
Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 13-29%), thrombocytopenia (range, 5-17%), and anemia (range, 0-13%) based on laboratory measurements occurred in patients with B-cell malignancies treated with single agent ibrutinib; monitor CBC monthly
Fatal and serious cases of renal failure have occurred; treatment-emergent increases in creatinine levels up to 1.5 x ULN occurred in 67% (MCL) and 23% (CLL) and from 1.5-3 x ULN in 9% (MCL) and 4% (CLL); periodically monitor creatinine levels and maintain hydration
Other malignancies (5-14%) reported including carcinomas (1-3%); the most frequent second primary malignancy was nonmelanoma skin cancer (4-11%)
Hypertension reported with a median time to onset of 4.6 months; monitor for new onset hypertension or hypertension that is not adequately controlled after initiating ibrutinib
Tumor lysis syndrome infrequently reported; assess the baseline risk (eg, high tumor burden) and take appropriate precautions
Based on findings in animals, can cause fetal harm when administered to a pregnant woman
Metabolized in the liver; although no clinical trials have been completed in patients with impaired hepatic function, ibrutinib systemic exposure was ~6-fold higher in patients (N=3) with moderate hepatic impairment (Child-Pugh B) compared to healthy volunteers
IMBRUVICA 140MG USES
Imbruvica 140 mg Capsule is used in the treatment of mantle-cell lymphoma and blood cancer (Chronic lymphocytic leukemia). It is also used in chronic lymphocytic leukaemia who have received at least one prior therapy or with 17p deletion.
IMBRUVICA 140MG STORAGE
Store at room temperature between 68-77°F (20-25°C)
Keep ibrutinib in the original container with the lid tightly closed
IMBRUVICA 140MG REVIEW
“Helpful team, good price for product imbruvica 140mg, fast delivery. Only thing that let it down was paying for delivery that was in an envelope and posted through letter box. Not sure what I was paying for regarding delivery. Saying that I would order again from strapcart.com.” – Halen Crew
Add paragraph text here.
